Rapid Rx Quiz: TNF Inhibitors

Mary L. Windle, PharmD


October 20, 2023

Tumor necrosis factor (TNF) inhibitor drugs target the TNF protein responsible for triggering inflammation as part of several disease processes in the human body that are part of the pathophysiology of inflammatory bowel diseases, rheumatologic joint conditions, and psoriasis. Examples of TNF inhibitors approved by the US Food and Drug Administration for these conditions include adalimumab, certolizumab, etanercept, golimumab, and infliximab. These agents can be used as monotherapy or in combination with other medications (eg, methotrexate, prednisone, leflunomide, hydroxychloroquine, sulfasalazine). They are specifically designed to treat inflammatory conditions, and can be administered by subcutaneous injection — weekly, every other week, or every 4 weeks — or by an intravenous infusion every 4-8 weeks.

Are you aware of the most recent research into TNF inhibitors and their indications, efficacy, and adverse effects? Take this short quiz to find out.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.